Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine IMA202-101)
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs IMA-202 (Primary)
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ACTengine
- Sponsors Immatics US
- 12 Jul 2019 Planned End Date changed from 1 Jun 2033 to 1 Jun 2022.
- 12 Jul 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 02 Jan 2019 Planned initiation date changed from 1 Mar 2018 to 1 Mar 2019.